On World Lung Day, a pharmaceutical firm has initiated a nationwide campaign aimed at increasing awareness about lung health and the importance of early detection and treatment of respiratory illnesses.
The theme for this year’s World Lung Day is “Access to prevention and treatment for all. Leave no one behind.”
Alkem Pharmaceuticals, in a statement, expressed its commitment to reaching every corner of India through this endeavour in response to the rising number of individuals suffering from respiratory ailments.
Alkem is coordinating 700 to 800 outreach programs across India
As part of its mission, Alkem is coordinating 700 to 800 outreach programs across India and partnering with nearly 100 hospitals in tier-1 and tier-2 cities.
Sudipta Roy, President and Head of Acute Business at Alkem Laboratories Limited, stated, “India bears a significant burden of chronic respiratory diseases (CRD), constituting 15.69 per cent of global CRD cases. What is even more alarming is that India accounts for an outsized 30.28 per cent of all global deaths attributed to CRD.” Among these CRDs, Chronic Obstructive Pulmonary Disease (COPD) is particularly prevalent in India, with a staggering 55.23 million cases, the highest globally.
India also ranks second globally in terms of COPD-related deaths, with nearly 0.85 million fatalities reported each year, Roy noted.
Additionally, the nation faces a grim reality concerning asthma, as India accounts for 43 per cent of global asthma-related fatalities, making it the leading country in terms of deaths caused by this condition, he stated.
“On this World Lung Day, Alkem Laboratories Limited is committed to promoting healthy lungs and the significance of inhalation therapy. We firmly believe that access to quality healthcare, including inhalation therapy, should be a fundamental right for every individual. Through our nationwide campaign, we aspire to raise awareness, educate the public, and ensure that no one is left behind in the battle against respiratory diseases,” Roy emphasized.
He also underscored the pivotal role of inhalation therapy in mainstream respiratory management, noting that it often serves as the primary treatment for lung diseases such as asthma and COPD.